Cargando…

Boceprevir and personalized medicine in hepatitis C virus infection

Boceprevir was the first agent, along with telaprevir, of a novel class of direct-acting antivirals that entered clinical practice for the treatment of chronic hepatitis C. Boceprevir is an antiprotease that directly blocks hepatitis C virus (HCV) replication. Two studies in patients with HCV genoty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habersetzer, François, Leboeuf, Céline, Doffoël, Michel, Baumert, Thomas F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513234/ https://www.ncbi.nlm.nih.gov/pubmed/23226068 http://dx.doi.org/10.2147/PGPM.S24259

Ejemplares similares

New developments in the management of hepatitis C virus infection: focus on boceprevir
por: Berenguer, Marina, et al.
Publicado: (2012)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial
por: Saviano, Antonio, et al.
Publicado: (2022)

Adaptive Immunity to Hepatitis C Virus
por: Zeisel, Mirjam B., et al.
Publicado: (2009)

Boceprevir: A new hope against hepatitis C virus
por: Brashier, Dick B. S., et al.
Publicado: (2012)

Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks
por: Murray, John M., et al.
Publicado: (2013)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Boceprevir
Publicado: (2012)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
por: Mehawej, Mireille, et al.
Publicado: (2015)

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary
por: Odhiambo, Raymond, et al.
Publicado: (2013)

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease
por: Howe, Anita Y. M., et al.
Publicado: (2013)

Boceprevir-induced Herpes Zoster
por: Babalı, Ayşegul, et al.
Publicado: (2018)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
por: Yang, Chi-Chieh, et al.
Publicado: (2015)

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
por: Zeisel, Mirjam B., et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation
por: Fafi-Kremer, Samira, et al.
Publicado: (2010)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
por: Mangia, Alessandra, et al.
Publicado: (2017)

Pleuro-Pulmonary Nocardiosis as Opportunistic Infection in a Patient with Chronic Hepatitis C under Combination Treatment with Pegylated Interferon, Ribavirin, and Boceprevir
por: Putz-Bankuti, Csilla, et al.
Publicado: (2013)

Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection
por: Fafi-Kremer, Samira, et al.
Publicado: (2012)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Host-targeting therapies for hepatitis C virus infection: current developments and future applications
por: Crouchet, Emilie, et al.
Publicado: (2018)

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
por: Ferrante, Shannon Allen, et al.
Publicado: (2013)

Acute pancreatitis associated with boceprevir: a case report
por: Bilar, Juliana Miguel, et al.
Publicado: (2014)

Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection
por: Heuschkel, Margaux J., et al.
Publicado: (2021)

Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
por: Kiser, Jennifer J., et al.
Publicado: (2017)

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
por: Howe, John A., et al.
Publicado: (2014)

Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection
por: Mayer, Pierre, et al.
Publicado: (2020)

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
por: Coilly, Audrey, et al.
Publicado: (2015)

New perspectives for preventing hepatitis C virus liver graft infection
por: Felmlee, Daniel J., et al.
Publicado: (2016)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip
por: Goto, Kaku, et al.
Publicado: (2020)

Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure
por: Colpitts, Che C., et al.
Publicado: (2016)

Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection
por: Verrier, Eloi R., et al.
Publicado: (2016)

Hepatitis C virus infection and related liver disease: the quest for the best animal model
por: Mailly, Laurent, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qn260o7dvcnfehlirni0kjrojs